Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
NEKTAR THERAPEUTICS
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
July 21, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
Nektar Therapeutics Reports First Quarter 2026 Financial Results
May 7, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
April 28, 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 23, 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
April 21, 2026
Nektar Therapeutics Announces Proposed Public Offering
April 20, 2026
1
2
Next Page
→